CLINICAL TRIALS PROFILE FOR CEFADROXIL

All Clinical Trials for CEFADROXIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00405158 ↗	Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding	Completed	Karlstad University	N/A	2002-01-01	The objective of the study was to test the hypothesis that acupuncture treatment hastens recovery time from inflammatory symptoms of the breast during breastfeeding. 205 mothers with 210 cases of breast inflammation (commonly called "mastitis") during breastfeeding were randomly assigned to one of three treatment groups. There were two groups where acupuncture was used and one without acupuncture. The mothers symptoms were recorded at the onset of health care contact and daily until recovery. All care interventions given, including antibiotic therapy, were monitored. Women who participated were asked to leave a breast milk sample to test for bacterial growth. It was found that acupuncture did not shorten the women's contacts with health care services but did improve their symptoms on contact days 3 and 4. It was seen in this study that only 15 % of women were prescribed antibiotics which was a very low rate of prescription compared to USA, Canada, Australia, Turkey and New Zealand where up to 100% are given antibiotics. Seven women (3.3% of those in the study) developed a breast boil and this is a similar number to a study in Australia where many more were treated by antibiotics. This could mean that many women throughout the world are given antibiotics when in fact they may recover without them. This is an important finding in relation to the fight against antibiotic resistant bacteria.
NCT00834275 ↗	Cefadroxil 500 mg Capsules Under Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2004-09-01	The objective of this study is to compare the relative bioavailability of cefadroxil 500 mg capsules (manufactured by Teva Pharmaceuticals USA) with that of DURICEF® 500 mg capsules (manufactured by Bristol-Myers Squibb Company) when dosed (1 x 500 mg capsules) in normal healthy non-smoking male and female subjects under fasting conditions.
NCT00835081 ↗	Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.	Completed	Teva Pharmaceuticals USA	Phase 1	2004-09-01	The objective of this study is to compare the relative bioavailability of cefadroxil 500 mg capsules (manufactured by Teva Pharmaceuticals USA) with that of DURICEF® 500 mg capsules (manufactured by Bristol-Myers Squibb Company) when dosed (1 x 500 mg capsules) in normal healthy non-smoking male and female subjects under fed conditions.
NCT01244698 ↗	Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction	Completed	Plastic Surgery Educational Foundation	Phase 4	2010-11-01	Antibiotics are used routinely in postoperative tissue expander based breast reconstruction (TE) and autologous flap (AF) breast reconstruction procedures. Closed suction drains are also used routinely in immediate breast reconstruction to prevent fluid accumulation and seroma formation at the surgical sites. Antibiotics are most often prescribed as a precaution since drains can be a source for infection by creating open channels to outside contaminants. Plastic surgery patients without closed suction drainage devices are usually not placed on prolonged postoperative antibiotics. Current preoperative surgical antibiotic prophylaxis is recommended for up to 24 hours only. These recommendations do not take into account the increased risk of indwelling closed suction drains. A recent survey of plastic surgeons, conducted by SBUMC investigators, (IRB# 129415) found that Plastic Surgeons are divided as to extended outpatient administration following TE breast reconstruction. The study plans to prospectively enroll patients who will undergo immediate breast reconstruction with TE or AF based breast reconstruction. Using the above data and the current protocol, the investigators will investigate the optimal antibiotic discontinuation period for these patients. The investigators hypothesize that the use of 24-hour perioperative antibiotics in TE or AF based immediate breast reconstruction with closed suction drainage, does not result in an increased infection rate compared to prolonged postoperative antibiotic administration.
NCT01244698 ↗	Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction	Completed	The Plastic Surgery Foundation	Phase 4	2010-11-01	Antibiotics are used routinely in postoperative tissue expander based breast reconstruction (TE) and autologous flap (AF) breast reconstruction procedures. Closed suction drains are also used routinely in immediate breast reconstruction to prevent fluid accumulation and seroma formation at the surgical sites. Antibiotics are most often prescribed as a precaution since drains can be a source for infection by creating open channels to outside contaminants. Plastic surgery patients without closed suction drainage devices are usually not placed on prolonged postoperative antibiotics. Current preoperative surgical antibiotic prophylaxis is recommended for up to 24 hours only. These recommendations do not take into account the increased risk of indwelling closed suction drains. A recent survey of plastic surgeons, conducted by SBUMC investigators, (IRB# 129415) found that Plastic Surgeons are divided as to extended outpatient administration following TE breast reconstruction. The study plans to prospectively enroll patients who will undergo immediate breast reconstruction with TE or AF based breast reconstruction. Using the above data and the current protocol, the investigators will investigate the optimal antibiotic discontinuation period for these patients. The investigators hypothesize that the use of 24-hour perioperative antibiotics in TE or AF based immediate breast reconstruction with closed suction drainage, does not result in an increased infection rate compared to prolonged postoperative antibiotic administration.
NCT01244698 ↗	Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction	Completed	Stony Brook University	Phase 4	2010-11-01	Antibiotics are used routinely in postoperative tissue expander based breast reconstruction (TE) and autologous flap (AF) breast reconstruction procedures. Closed suction drains are also used routinely in immediate breast reconstruction to prevent fluid accumulation and seroma formation at the surgical sites. Antibiotics are most often prescribed as a precaution since drains can be a source for infection by creating open channels to outside contaminants. Plastic surgery patients without closed suction drainage devices are usually not placed on prolonged postoperative antibiotics. Current preoperative surgical antibiotic prophylaxis is recommended for up to 24 hours only. These recommendations do not take into account the increased risk of indwelling closed suction drains. A recent survey of plastic surgeons, conducted by SBUMC investigators, (IRB# 129415) found that Plastic Surgeons are divided as to extended outpatient administration following TE breast reconstruction. The study plans to prospectively enroll patients who will undergo immediate breast reconstruction with TE or AF based breast reconstruction. Using the above data and the current protocol, the investigators will investigate the optimal antibiotic discontinuation period for these patients. The investigators hypothesize that the use of 24-hour perioperative antibiotics in TE or AF based immediate breast reconstruction with closed suction drainage, does not result in an increased infection rate compared to prolonged postoperative antibiotic administration.

Clinical Trial Conditions for CEFADROXIL

Condition Name

Condition Name for CEFADROXIL
Intervention	Trials
Healthy	3
Atrial Fibrillation	1
Pyomyositis	1
Bacterial Infection	1

Condition MeSH

Condition MeSH for CEFADROXIL
Intervention	Trials
Arthritis, Infectious	1
Kidney Calculi	1
Urinary Tract Infections	1
Infections	1

Clinical Trial Locations for CEFADROXIL

Trials by Country

Trials by Country for CEFADROXIL
Location	Trials
United States	6
Egypt	2
Canada	2
Brazil	1
Singapore	1

Trials by US State

Trials by US State for CEFADROXIL
Location	Trials
Texas	2
Pennsylvania	1
Colorado	1
Kansas	1
New York	1

Clinical Trial Progress for CEFADROXIL

Clinical Trial Phase

Clinical Trial Phase for CEFADROXIL
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CEFADROXIL
Clinical Trial Phase	Trials
Completed	11
Enrolling by invitation	1

Clinical Trial Sponsors for CEFADROXIL

Sponsor Name

Sponsor Name for CEFADROXIL
Sponsor	Trials
Teva Pharmaceuticals USA	2
GlaxoSmithKline	2
University of Colorado, Denver	1

Sponsor Type

Sponsor Type for CEFADROXIL
Sponsor	Trials
Other	10
Industry	6

Cefadroxil Clinical Trials Update, Market Analysis, and Generic/Biosimilar Projection

Last updated: May 22, 2026

Cefadroxil, an oral first-generation cephalosporin (active ingredient cefadroxil monohydrate), is off-patent in key markets and is widely generic. Clinical-trial activity is limited and concentrated in small studies, bioequivalence programs, or older infection indications rather than new large late-stage efficacy programs. Market growth is modest and driven by generic volume, antimicrobial stewardship constraints, and formulary access rather than pipeline breakthroughs.

What is the current clinical trials landscape for cefadroxil?

Are there active Phase 2 or Phase 3 cefadroxil trials?

No complete, current, publicly verifiable Phase 2/Phase 3 clinical-trial dataset is available in this workspace to support a precise “active trials” statement (trial counts, identifiers, study phases, recruitment status, and readouts). This prevents a complete, accurate update.

What types of cefadroxil studies still show up in clinical research?

Where cefadroxil appears in contemporary clinical research, it typically falls into:

• Bioequivalence studies for oral solid dosage forms (tablets, capsules).
• Comparative studies vs other oral antibiotics for acute bacterial infections, often with modest enrollment.
• Formulation/administration-adjacent studies (food effects, pediatric sampling, dosing schedules).
• Retrospective observational analyses of prescribing patterns and safety outcomes (these are not interventional trials).

How big is the cefadroxil market and what drives demand?

What are the core use cases for cefadroxil?

Cefadroxil is used for susceptible bacterial infections, historically including:

• Skin and skin structure infections
• Pharyngitis/tonsillitis (streptococcal disease in appropriate contexts)
• Uncomplicated urinary tract infections in susceptible pathogens
• Dental infections in select regimens
• Otitis media in pediatric contexts in some settings

Demand drivers are therefore:

• Diagnosis and prescribing incidence for community bacterial infections
• Antimicrobial stewardship and resistance patterns that affect preferred antibiotic selection
• Generic price competition and payer formulary placement
• Pediatric and primary care prescribing behavior

What is the market structure?

Cefadroxil is a generic-heavy market. In most geographies, the market behaves like a commodity antibiotic:

• Low pricing power
• Short commercial advantage windows for individual manufacturers
• Volume competition based on distribution strength and rebate positioning
• Sporadic launches tied to new packaging strengths, label updates, or supply chain availability

When does cefadroxil lose exclusivity and what does that mean commercially?

Is cefadroxil under patent or regulatory exclusivity protection today?

Cefadroxil is widely marketed as a generic product across major markets, indicating the active regulatory and patent exclusivity has long since lapsed for the original innovator approvals. As a result, commercial exposure is dominated by ongoing generic competition rather than a pending exclusivity cliff.

What commercial implication follows once exclusivity ends?

Once exclusivity ends, cefadroxil typically experiences:

• Rapid erosion of branded pricing
• Expansion of generic SKU counts
• Lower margins concentrated among manufacturers with scale and supply reliability
• Less differentiation, so market share shifts with distribution and tender wins

What generic entry risks exist for cefadroxil?

Are there Paragraph IV filing scenarios for cefadroxil?

For off-patent generics of established oral antibiotics, Paragraph IV filing relevance is usually limited unless late-expiring secondary patents exist (formulation, polymorph, manufacturing, or method-of-use). A precise litigation/Paragraph IV profile cannot be produced here because no Orange Book listing set and no lawsuit docket data is available in this workspace.

What non-Orange Book risks can still delay entry?

Even without patent barriers, entry can be delayed by:

• CMC readiness and bioequivalence package completeness
• Narrow therapeutic-range labeling issues (less common for cefadroxil than for complex generics)
• Shortage dynamics for antibiotic APIs and key intermediates
• Local regulatory inspection outcomes affecting manufacturing approvals
• Labeling changes that require supplements (pediatric dosing, updated susceptibility wording)

How does cefadroxil compare with competing oral antibiotics?

What are the main competitive classes?

Cefadroxil competes primarily with:

• Other oral cephalosporins (e.g., cephalexin and other first-generation agents)
• Penicillins (amoxicillin-class)
• Macrolides (e.g., azithromycin) in respiratory indications
• Doxycycline (where stewardship and guideline choices align)
• Fluoroquinolones in limited contexts where appropriate
• Clindamycin in specific skin/dental patterns

Where does cefadroxil tend to fit best?

In real-world prescribing, cefadroxil often holds share when:

• Clinicians choose a beta-lactam for susceptible organisms
• Pediatric-friendly dosing and tolerability supports selection
• Formularies prefer covered generics in the cephalosporin bucket
• Allergy history supports cephalosporin use more than certain penicillin regimens

What is the FDA regulatory status of cefadroxil and how does it affect market supply?

What is the likely regulatory pathway?

Cefadroxil generics generally rely on abbreviated approval pathways (ANDA) under US FDA frameworks for generic drugs. Each generic product is regulated by:

• Bioequivalence to a listed reference product
• Chemistry, manufacturing, controls (CMC)
• Labeling adequacy and updates consistent with current safety communications

Does FDA oversight constrain total supply?

Yes, but the main constraint is manufacturing compliance and inspections rather than regulatory exclusivity. For commodity antibiotics, supply can still tighten during:

• API and intermediate shortages
• Quality remediation programs
• Export/import bottlenecks
• Manufacturing site-specific compliance actions

What is the projected cefadroxil market outlook (2025-2030)?

Base case projection: modest growth, margin compression

For off-patent oral generics, the base case projection typically looks like:

• Volume growth or stability that tracks underlying community infection incidence
• Continued share churn among generic suppliers
• Ongoing price pressure as new ANDA entrants and pack-size arbitrage emerge
• Margin compression driven by procurement auctions and payer contracting

Downside scenario: stewardship and resistance shifts reduce share

Cefadroxil share can decline if:

• Guidelines shift preference away from first-generation cephalosporins for key indications
• Resistance patterns reduce susceptibility coverage in local antibiograms
• Stewardship programs reduce use of older broad-spectrum cephalosporins

Upside scenario: pediatric/formulary wins and supply stability

Share can increase if:

• Formulary changes favor covered beta-lactams with favorable cost
• Supplier reliability improves during regional shortages
• Pediatric dosing strengths match prescribing patterns and reduce switching

Key projection metrics to track (commercial and pipeline)

• Number of available generic SKUs per strength/formulation
• Average wholesale price (AWP) and net price trends from payer contracting
• Tender and hospital procurement awards by region
• Availability metrics: stock-out rates, lead times, and manufacturer market exits/returns
• Antibiogram trends in the therapeutic settings where cefadroxil is used

What patent estate issues could still affect cefadroxil competition?

Are there still “secondary” patents (formulation, polymorph, method-of-use)?

Even after primary composition-of-matter patents expire, antibiotics sometimes have:

• Formulation patents (excipients, solid-state forms, particle size)
• Manufacturing process patents (crystallization, filtration, drying steps)
• Method-of-use patents tied to dosing schedules or specific patient subgroups

This analysis cannot name specific cefadroxil patents or expiration dates without Orange Book and patent family data in this workspace.

What is the litigation landscape likely to look like?

In mature generic markets, litigation typically becomes:

• Incidental to product entry (older ANDA cases resolved long ago)
• Secondary to manufacturing changes or label updates
• More prominent in jurisdictions where reference products or device/formulation variants create new disputes

How many markets matter for cefadroxil and what changes the economics?

US vs EU vs other geographies

Economics depend on:

• Generic procurement intensity (tenders, reference pricing, HTA constraints)
• Patent litigation and regulatory enforcement strength
• Regulatory acceptance of multiple equivalent manufacturers
• Local antibiotic stewardship rules and prescribing guidelines

In most high-income markets, cefadroxil behaves like a low-cost generic with supply-driven competition. In lower-income markets, pricing and procurement cycles can be more volatile due to supply chain resilience and reimbursement structures.

Key Takeaways

• Cefadroxil is a generic-dominated oral antibiotic market with limited evidence of late-stage clinical innovation in public late-phase categories.
• Commercial outlook is primarily driven by generic supply, pricing pressure, and formulary access rather than new exclusivity or pipeline tailwinds.
• Risk to demand comes from antimicrobial stewardship and local resistance patterns shifting antibiotic choice away from first-generation cephalosporins.
• Upside is tied to payer wins, pediatric or community prescribing fit, and manufacturing supply stability.

FAQs

What indications drive the majority of cefadroxil prescriptions?

Community bacterial infections, including skin/soft tissue and certain respiratory/dental indications, plus selected urinary tract infections where susceptibility supports cephalosporin use.

Are cefadroxil generics interchangeable at the tablet/capsule strength level?

They are generally considered therapeutically substitutable when approved as bioequivalent ANDA products, but product-specific excipients and dosing instructions can differ.

What happens to cefadroxil pricing when a new generic enters?

Expect additional price competition and faster margin compression, with net price declines driven by contracting and tender outcomes rather than wholesale list price.

Does cefadroxil face biosimilar competition?

No. Cefadroxil is a small-molecule antibiotic and does not have biosimilar dynamics.

How should clinicians think about resistance and guideline shifts for cefadroxil?

Clinicians rely on local susceptibility data and guideline recommendations that may narrow recommended use of older cephalosporins depending on resistance patterns.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. (Accessed 2026-05-22).
2. ClinicalTrials.gov. Search results for “cefadroxil.” US National Library of Medicine. (Accessed 2026-05-22).